Literature DB >> 2885701

Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin.

W A Murphy, V A Lance, S Moreau, J P Moreau, D H Coy.   

Abstract

Analogs of a potent octapeptide analog of somatostatin (SRIF) H-(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Thr(NH2) were synthesized. Aromatic substitutions for Tyr resulted in little change in inhibitory potency on growth hormone (GH) secretion in the rat. Substitutions for Val or (D)Trp resulted in analogs with diminished activity. Substitution of (D)Nal for (D)Phe increased duration of GH inhibition. Final weights of subcutaneously implanted prostate tumors (R3327) were 41% lower in rats treated with an N-terminal 4-chloro-(D)phenylalanyl analog as compared to vehicle treated controls. The analog had no effect on testicular weight or final plasma testosterone levels. SRIF analogs may represent an alternative treatment for prostate cancer that would be free of the untoward reproductive effects of other treatments (e.g. LH-RH or castration).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885701     DOI: 10.1016/0024-3205(87)90073-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Somatostatin analogues: are they analogues of somatostatin?

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 2.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

3.  Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014.

Authors:  J M Kuhn; C Basin; M Mollard; B de Rougé; C Baudoin; R Obach; G Tolis
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer.

Authors:  H Parmar; C D Charlton; R H Phillips; L Edwards; J L Bejot; F Thomas; S L Lightman
Journal:  Clin Exp Metastasis       Date:  1992-01       Impact factor: 5.150

5.  Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

Authors:  Renzo Cescato; Judith Erchegyi; Beatrice Waser; Véronique Piccand; Helmut R Maecke; Jean E Rivier; Jean Claude Reubi
Journal:  J Med Chem       Date:  2008-06-11       Impact factor: 7.446

Review 6.  Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate.

Authors:  M A Noordzij; G J van Steenbrugge; T H van der Kwast; F H Schröder
Journal:  Urol Res       Date:  1995

7.  Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

Authors:  Jaume Capdevila; Isabel Sevilla; Vicente Alonso; Luís Antón Aparicio; Paula Jiménez Fonseca; Enrique Grande; Juan José Reina; José Luís Manzano; Juan Domingo Alonso Lájara; Jorge Barriuso; Daniel Castellano; Javier Medina; Carlos López; Ángel Segura; Sergio Carrera; Guillermo Crespo; José Fuster; Javier Munarriz; Pilar García Alfonso
Journal:  BMC Cancer       Date:  2015-07-04       Impact factor: 4.430

Review 8.  Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

Authors:  Rosa Maria Paragliola; Roberto Salvatori
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-07       Impact factor: 5.555

9.  Inhibitory effect of a somatostatin analogue (SMS 201-995) on the growth of androgen-dependent mouse mammary tumor (Shionogi carcinoma 115).

Authors:  S Noguchi; Y Nishizawa; K Motomura; H Inaji; S Imaoka; H Koyama; K Matsumoto
Journal:  Jpn J Cancer Res       Date:  1993-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.